This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weinreich, D. M. Articles by Alexander, H. R. Search for Related Content PubMed PubMed Citation Articles by Weinreich, D. M. Articles by Alexander, H. R.

Effect of Interleukin 1 Receptor Antagonist Gene Transduction on Human Melanoma Xenografts in Nude Mice

The Surgical Metabolism Section [D. M. W., D. M. E., M. P., N. M. C., E. D. F., E. M. T., H. R. A.] and Immunology Section [P. J. S.], Surgery Branch and the Laboratory of Pathology [S. M. H.], Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892

Interleukin (IL)-1 is a pleiotropic inflammatory cytokine that promotes angiogenesis and enhances tumor growth and metastases. We evaluated the effects of IL-1 receptor antagonist (IL-1ra) on tumor growth and metastases in human melanoma xenografts. We selected two human melanoma lines (SMEL and PMEL) with differential (high versus low, respectively) constitutive production of IL-1 by ELISA. The IL-1ra gene was isolated from monocyte RNA by PCR and retrovirally transduced into SMEL and PMEL. In vitro cell proliferation was evaluated using a WST-1 assay. Athymic nude mice received s.c. or i.v. injection with parental, vector-transduced, or IL-1ra-transduced melanoma cells, and tumor growth, lung metastases, and histology were characterized. IL-1 was produced by SMEL in vitro and ex vivo (117 and 67 pg/ml/10⁶ cells/24 h, respectively), but not by PMEL (15 and 0 pg/ml/10⁶ cells/24 h, respectively). Neither made IL-1ra natively. Gene-transduced cell lines secreted >1000 pg/ml/10⁶ cells/24 h of IL-1ra by ELISA. In vitro proliferation of each parental cell line was comparable to the proliferation rate of each transduced cell line. IL-1ra-transduced SMEL (SMEL/IL-1ra) showed significantly slower tumor growth compared with null-transduced and parental cell lines (P < 0.001, ANOVA-Bonferroni/Dunn). There was no difference in growth rates between PMEL and IL-1ra-transduced PMEL (PMEL/IL-1ra). A mixing study of SMEL and SMEL/IL-1ra showed significant inhibition of tumor growth at various ratios (P < 0.001, ANOVA-Bonferroni/Dunn). There were significantly fewer lung metastases with SMEL/IL-1ra versus SMEL (P < 0.002). IL-1ra decreases in vivo growth and metastatic potential of a human melanoma xenograft that constitutively secretes IL-1. This effect may be exploitable using clinically available IL-1ra for the treatment of human cancers.

This article has been cited by other articles:

				Y. Krelin, E. Voronov, S. Dotan, M. Elkabets, E. Reich, M. Fogel, M. Huszar, Y. Iwakura, S. Segal, C. A. Dinarello, et al. Interleukin-1{beta}-Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen-Induced Tumors Cancer Res., February 1, 2007; 67(3): 1062 - 1071. [Abstract] [Full Text] [PDF]

				D. M. Elaraj, D. M. Weinreich, S. Varghese, M. Puhlmann, S. M. Hewitt, N. M. Carroll, E. D. Feldman, E. M. Turner, and H. R. Alexander The Role of Interleukin 1 in Growth and Metastasis of Human Cancer Xenografts Clin. Cancer Res., February 15, 2006; 12(4): 1088 - 1096. [Abstract] [Full Text] [PDF]

				H. R. Alexander Jr. A Motion for Cautious Optimism in the Treatment of Patients With Ocular Melanoma: The Ayes Have It Ann. Surg. Oncol., June 1, 2005; 12(6): 417 - 419. [Full Text] [PDF]

				P. G. Gallagher, Y. Bao, A. Prorock, P. Zigrino, R. Nischt, V. Politi, C. Mauch, B. Dragulev, and J. W. Fox Gene Expression Profiling Reveals Cross-talk between Melanoma and Fibroblasts: Implications for Host-Tumor Interactions in Metastasis Cancer Res., May 15, 2005; 65(10): 4134 - 4146. [Abstract] [Full Text] [PDF]

				F. Graziano, A. Ruzzo, D. Santini, B. Humar, G. Tonini, V. Catalano, R. Berardi, F. Pizzagalli, F. Arduini, I. Bearzi, et al. Prognostic Role of Interleukin-1{beta} Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer J. Clin. Oncol., April 1, 2005; 23(10): 2339 - 2345. [Abstract] [Full Text] [PDF]

				Y. Sato, K. Harada, K. Kizawa, T. Sanzen, S. Furubo, M. Yasoshima, S. Ozaki, M. Ishibashi, and Y. Nakanuma Activation of the MEK5/ERK5 Cascade Is Responsible for Biliary Dysgenesis in a Rat Model of Caroli's Disease Am. J. Pathol., January 1, 2005; 166(1): 49 - 60. [Abstract] [Full Text] [PDF]